Cyclooxygenase-2 Induction after Oral Surgery Does Not Entirely Account for Analgesia after Selective Blockade of Cyclooxygenase 2 in the Preoperative Period

Background:The administration of selective cyclooxygenase-2 inhibitors before surgery is regarded as an innovative option to manage postoperative pain. This study was designed to (1) examine the efficacy of preoperative cyclooxygenase-2 blockade on postoperative oral pain and (2) compare pain intensity with prostaglandin E2 (PGE2) production and cyclooxygenase isoform (cyclooxygenase-1, cyclooxygenase-2) messenger RNA (mRNA) expression at the surgical site during the postoperative period. Methods:Sixty patients with impacted lower third molars were randomly allocated to three single-dose treatment groups—placebo, 50 mg rofecoxib, or 550 mg naproxen—1 h before extraction. Pain intensity was evaluated with categorical and visual analog scales every 30 min from 90 to 240 min after surgery. At these times, PGE2 production in the alveolar socket was also evaluated. Cyclooxygenase-1 and cyclooxygenase-2 mRNA expression was examined by reverse-transcription polymerase chain reaction in gingival specimens collected during tooth removal and 240 min after surgery. Results:Pain intensity and PGE2 production in the placebo group increased throughout the observation period. Naproxen prevented pain and decreased PGE2 release at all time points. Rofecoxib reduced PGE2 production versus placebo from 150 min onward, while inducing analgesia through the whole observation period. mRNA assay in gingival specimens collected at tooth extraction revealed cyclooxygenase-1 expression, whereas cyclooxygenase 2 was undetectable. At the end of observation, cyclooxygenase-1 mRNA expression was unchanged, whereas cyclooxygenase-2 mRNA was significantly induced. Conclusions:This study indicates that preoperative administration of a selective cyclooxygenase-2 inhibitor ensures effective control of postoperative pain. It is suggested that the selective blockade of inducible cyclooxygenase 2 at the surgical site does not entirely account for the analgesic action occurring in the postoperative period.

[1]  J. Eisenach,et al.  Preoperative Inhibition of Cyclooxygenase-1 in the Spinal Cord Reduces Postoperative Pain , 2005, Anesthesia and analgesia.

[2]  E. Kharasch,et al.  Central Nervous System Concentrations of Cyclooxygenase-2 Inhibitors in Humans , 2005, Anesthesiology.

[3]  Cristina Vassalle,et al.  Gastrin promotes human colon cancer cell growth via CCK‐2 receptor‐mediated cyclooxygenase‐2 induction and prostaglandin E2 production , 2005, British journal of pharmacology.

[4]  C. Pashos,et al.  Making Progress in the Management of Postoperative Pain: A Review of the Cyclooxygenase 2–Specific Inhibitors , 2004, Pharmacotherapy.

[5]  P. Wiffen,et al.  Relative efficacy of oral analgesics after third molar extraction , 2004, British Dental Journal.

[6]  M. Henry,et al.  Preoperative nonsteroidal anti-inflammatory agents: review of the literature. , 2004, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[7]  H. Wässle,et al.  GlyR α3: An Essential Target for Spinal PGE2-Mediated Inflammatory Pain Sensitization , 2004, Science.

[8]  J. Mitchell,et al.  Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  P. White,et al.  Perioperative Rofecoxib Improves Early Recovery After Outpatient Herniorrhaphy , 2004, Anesthesia and analgesia.

[10]  P. Mantyh,et al.  Constitutive Spinal Cyclooxygenase-2 Participates in the Initiation of Tissue Injury-Induced Hyperalgesia , 2004, The Journal of Neuroscience.

[11]  A. Bartoli,et al.  COX-2 selective inhibitors: a literature review of analgesic efficacy and safety in oral-maxillofacial surgery. , 2004, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[12]  T. Halaszynski,et al.  Preoperative Rofecoxib Oral Suspension as an Analgesic Adjunct After Lower Abdominal Surgery: The Effects on Effort-Dependent Pain and Pulmonary Function , 2004, Anesthesia and analgesia.

[13]  A. Rosenberg,et al.  Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial. , 2003, JAMA.

[14]  J. Eisenach,et al.  Cyclooxygenase-1 in the spinal cord plays an important role in postoperative pain , 2003, Pain.

[15]  Stephanie B. Jones,et al.  Cost-efficacy of Rofecoxib versus Acetaminophen for Preventing Pain after Ambulatory Surgery , 2002, Anesthesiology.

[16]  C. Woolf,et al.  A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. , 2002, Anesthesiology.

[17]  C. Woolf,et al.  Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. , 2002, Trends in molecular medicine.

[18]  S. Gordon,et al.  Peripheral prostanoid levels and nonsteroidal anti‐inflammatory drug analgesia: Replicate clinical trials in a tissue injury model , 2002, Clinical pharmacology and therapeutics.

[19]  R. Dionne,et al.  In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model , 2002, Clinical pharmacology and therapeutics.

[20]  R. Sinatra.  Role of COX-2 inhibitors in the evolution of acute pain management. , 2002, Journal of pain and symptom management.

[21]  P. Cooper,et al.  Evaluation of Preoperative Administration of the Cyclooxygenase-2 Inhibitor Rofecoxib for the Treatment of Postoperative Pain after Lumbar Disc Surgery , 2002, Neurosurgery.

[22]  S. Gordon,et al.  Analgesia and COX-2 inhibition. , 2001, Clinical and experimental rheumatology.

[23]  P. Isakson,et al.  The Acute Antihyperalgesic Action of Nonsteroidal, Anti-Inflammatory Drugs and Release of Spinal Prostaglandin E2 Is Mediated by the Inhibition of Constitutive Spinal Cyclooxygenase-2 (COX-2) but not COX-1 , 2001, The Journal of Neuroscience.

[24]  J. Vane,et al.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  I. Bjarnason,et al.  COX-2 inhibitors , 1999, The Lancet.

[26]  T. Hla,et al.  Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Svensson,et al.  The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. , 2002, Annual review of pharmacology and toxicology.